Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Oct 18, 2025, 16:59Raul Santos Gave 2 Talks at SAC 2025: On The Role of LDL-C and Future of Lipid-lowering Therapies
-
Oct 18, 2025, 16:57Marilena Vrana: What An Inspiring Week at The 2025 Plasma Protein Forum and Business Forum
-
Oct 18, 2025, 16:53Caitlin Raymond: When Technology Meets Physiology in Neonatal Patients
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 18, 2025, 16:56Alexandra Whiteside on Improving Coagulation Kinetics
-
Oct 18, 2025, 16:52Wolfgang Miesbach on Differential Diagnosis of Thrombocytopenia
-
Oct 18, 2025, 16:49Arisa Chuklin, Thita Joy Chiasakul, and Noppacharn Uaprasert on Management of Thrombosis in Behçet’s Syndrome
-
Oct 18, 2025, 16:47State of the Art Review On Angina After PCI From Javier Escaned's Team
-
Oct 18, 2025, 16:25Luciana Werneck Zuccherato and Colleagues on A3 domain of FVIII in Severe Hemophilia A
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 18, 2025, 16:55Emilia Arturo: Your Reminder to Donate Blood If You Can, When You Can
-
Oct 18, 2025, 16:51Allison Wheeler Rallies Support for Magdalena Lewandowska's NYC Marathon Run Benefiting NBDF
-
Oct 17, 2025, 16:07WFH Volunteer Mary Byrne Transforms Bleeding Disorder Diagnostics
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success